Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
0.2883
-0.0137 (-4.54%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
559,753
Open
0.2998
Bid (Size)
0.2900 (18)
Ask (Size)
0.2949 (5)
Prev. Close
0.3020
Today's Range
0.2840 - 0.3087
52wk Range
0.2840 - 14.22
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
September 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Performance
YTD
-94.34%
-94.34%
1 Month
-17.46%
-17.46%
3 Month
-69.08%
-69.08%
6 Month
-88.87%
-88.87%
1 Year
-92.96%
-92.96%
More News
Read More
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
August 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why Is SciSparc (SPRC) Stock Up 94% Today?
August 15, 2024
Via
InvestorPlace
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
August 29, 2024
Via
Benzinga
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
August 28, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
August 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
August 20, 2024
Via
Benzinga
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
August 19, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
August 19, 2024
Via
Benzinga
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
August 19, 2024
Via
Benzinga
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
August 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Nasdaq Jumps Over 2%; Walmart Earnings Top Views
August 15, 2024
Via
Benzinga
Dow Surges Over 500 Points; US Retail Sales Rise In July
August 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
August 15, 2024
Via
InvestorPlace
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
August 15, 2024
Via
Benzinga
SciSparc Updates Regarding the Status of the AutoMax Merger
August 14, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 16, 2024
Via
Benzinga
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.